Additional Resources

Soliris Web Site

Provides information about PNH and Soliris for patients and healthcare professionals. Sponsored by Alexion.

PNH Source

Provides information about PNH for patients and healthcare professionals. Sponsored by Alexion.

Eurordis – European Organization for Rare Diseases

Eurordis is dedicated to helping people with rare diseases and assisting the organizations that serve them.

Orphanet

Orphanet is a database of information on rare diseases and orphan drugs for all publics. Its aim is to contribute to the improvement of the diagnosis, care and treatment of patients with rare diseases.

National Organization for Rare Disorders (NORD)

NORD is dedicated to helping people with rare diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research and service.

PNH Foundation

An organization dedicated to raising funds for PNH research and helping families with disease-related expenses not covered by insurance.

Aplastic Anemia & MDS International Foundation (AA-MDSIF)

AA-MDSIF is a nonprofit patient organization that serves as a resource for patient assistance, patient education advocacy and support. The organization supports research to find treatments and potential cures for aplastic anemia (AA), myelodysplastic syndromes (MDS), and related bone marrow diseases including PNH. The AA-MDSIF website provides educational materials and medical information about AA, MDS, and PNH.



IMPORTANT SAFETY INFORMATION

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

Soliris® increases the risk of meningococcal infections

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).